Yahoo · Nov 4, 2026
Lifecore Biomedical: Q3 Earnings Snapshot
(AP) — Lifecore Biomedical, Inc. (LFCR) on Wednesday reported a loss of $40.
NASDAQ · LFCR
Healthcare · Drug Manufacturers - Specialty & Generic
$6.39
Up+$0.02 (+0.31%)
Updated Nov 21, 2026, 8:25 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LFCR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 20, 2026
LFCR closed at $6.39 after 21 trading sessions, down 0.16% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 20, 2026 | $6.37 | $6.39 | $6.369 | $6.39 | 218.74K |
| Nov 19, 2026 | $6.39 | $6.40 | $6.345 | $6.37 | 319.06K |
| Nov 18, 2026 | $6.40 | $6.41 | $6.39 | $6.40 | 147.54K |
| Nov 17, 2026 | $6.41 | $6.42 | $6.39 | $6.39 | 192.77K |
| Nov 16, 2026 | $6.41 | $6.42 | $6.40 | $6.415 | 65.92K |
| Nov 13, 2026 | $6.40 | $6.42 | $6.38 | $6.42 | 94K |
| Nov 12, 2026 | $6.38 | $6.40 | $6.38 | $6.40 | 109.89K |
| Nov 11, 2026 | $6.37 | $6.40 | $6.37 | $6.40 | 149.72K |
| Nov 10, 2026 | $6.37 | $6.385 | $6.37 | $6.37 | 369.58K |
| Nov 9, 2026 | $6.38 | $6.39 | $6.36 | $6.37 | 142.91K |
| Nov 6, 2026 | $6.38 | $6.39 | $6.36 | $6.36 | 780.49K |
| Nov 5, 2026 | $6.45 | $6.45 | $6.375 | $6.40 | 700.06K |
| Nov 4, 2026 | $6.44 | $6.45 | $6.41 | $6.44 | 270.83K |
| Nov 3, 2026 | $6.41 | $6.44 | $6.405 | $6.42 | 297.92K |
| Nov 2, 2026 | $6.40 | $6.42 | $6.375 | $6.39 | 800.23K |
| Oct 30, 2026 | $6.48 | $6.4992 | $6.315 | $6.40 | 1.02M |
| Oct 29, 2026 | $6.52 | $6.52 | $6.47 | $6.52 | 240.91K |
| Oct 28, 2026 | $6.44 | $6.51 | $6.43 | $6.51 | 365.16K |
| Oct 27, 2026 | $6.36 | $6.44 | $6.36 | $6.44 | 441.61K |
| Oct 26, 2026 | $6.41 | $6.44 | $6.40 | $6.44 | 436.37K |
| Oct 23, 2026 | $6.36 | $6.40 | $6.36 | $6.40 | 224.04K |
The latest Smart Investors Daily articles mentioning LFCR.
Company
Market Activity
Research & News
LFCR research
Company profile and research snapshot.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | Barrington Research | Market Perform | — |
| Sep 28, 2026 | William Blair | Market Perform | — |
| Jun 16, 2026 | Barrington Research | Outperform | — |
| Apr 29, 2026 | Barrington Research | Outperform | — |
| Mar 27, 2026 | Barrington Research | Outperform | — |
No generated briefing is available yet.
Yahoo · Nov 4, 2026
(AP) — Lifecore Biomedical, Inc. (LFCR) on Wednesday reported a loss of $40.
Yahoo · Nov 4, 2026
-- Multiple New Business Wins Continue to Strengthen Growing Pipeline -- CHASKA, Minn., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the third quarter and nine months ended September 30, 2026. CEO Commentary “During the third quarter, Lifecore secured two new technology transfer projects. One will support process performance qualific
Benzinga · Nov 4, 2026
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.28) by 285.71 percent. This is a 285.71 percent decrease over losses of $(0.28) per
Yahoo · Oct 23, 2026
Diranko Capital, an independent investment management firm, released its Q3 2026 investor letter. The letter can be downloaded here. In the quarter, Diranko Capital achieved a 2.2% after-fee return, matching the MSCI ACWI and outperforming the MSCI World Small Cap (-2.9%). Since inception, the firm has delivered a 14.7% annualized after-fee return, exceeding both benchmark […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning LFCR.